ROCKVILLE, Md., Jan. 3, 2023
/PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced
that it will present at the 41st Annual J.P. Morgan Healthcare
Conference on Tuesday, January 10,
2023.
41st Annual J.P. Morgan Healthcare
Conference
Date: Tuesday, January 10, 2023
Fireside chat: 11:15 a.m. PT
Location: Westin St. Francis, San Francisco, CA
A live webcast of the fireside chat can be accessed in the
Investors section of REGENXBIO's website at www.regenxbio.com. An
archived replay of the webcast will be available in the Investors
section of REGENXBIO's website for approximately 30 days following
the presentation.
About REGENXBIO Inc.
REGENXBIO is a leading clinical-stage biotechnology company
seeking to improve lives through the curative potential of gene
therapy. REGENXBIO's NAV Technology Platform, a proprietary
adeno-associated virus (AAV) gene delivery platform, consists of
exclusive rights to more than 100 novel AAV vectors, including
AAV7, AAV8, AAV9 and AAVrh10. REGENXBIO and its third-party NAV
Technology Platform Licensees are applying the NAV Technology
Platform in the development of a broad pipeline of candidates,
including late-stage and commercial programs, in multiple
therapeutic areas. REGENXBIO is committed to a "5x'25" strategy to
progress five AAV Therapeutics from our internal pipeline and
licensed programs into pivotal-stage or commercial products by
2025.
Contacts:
Dana Cormack
Corporate Communications
dcormack@regenxbio.com
Investors:
Chris Brinzey, ICR
Westwicke
339-970-2843
chris.brinzey@westwicke.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/regenxbio-announces-presentation-at-the-41st-annual-jp-morgan-healthcare-conference-301712108.html
SOURCE REGENXBIO Inc.